Anti-IL-17 (MCAF5352A (Afasevikumab))

Anti-IL-17 [MCAF5352A (Afasevikumab)], Recombinant, IgG1 kappa, Human

CloneID: MCAF5352A (Afasevikumab)

Antigen Long Description: The original antibody was produced by immunizing HuMab® mice with human IL-17.

Origin Pub PMID: 31779513

Buffer Composition: PBS with 0.02% Proclin 300.

Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7

Specificity Statement: This antibody is specific for human IL-17A and human IL-17F. It also binds their respective dimers — IL-17AA, IL-17AF, and IL-17FF.

Application Notes (Clone): This antibody successfully completed phase I clinical trials (Mitra et al., 2014; PMID: 25398489). The pharmacokinetics of this antibody and the post-dose levels of IL-17AA and IL-17FF in healthy were assessed as part of the phase I study (Peng et al., 2018; PMID: 30547287). The crystal structure of the Fab version of this antibody was resolved, and its binding kinetics (K_D) was measured at 7.78 ± 0.23 pM. Furthermore, alterations to the antibody's aromatic residues in its binding site and their effect on binding kinetics were assessed (Tilegenova et al., 2020; PMID: 31779513).

• SKU: ABAAb04236-10.0
• Manufacturer: Absolute Antibody
• Manufacturer SKU: Ab04236-10.0
• Package Unit: 100 μg
• Quantity Unit: STK
• Reactivity: Human
• Clonality: Recombinant
• Application: ELISA, Blocking, Neutralization, Super-Resolution Microscopy
• Isotype: IgG1 kappa
• Host: Human